参考文献/References:
[1] Collins AJ,Foley RN,Chavers B,et al. US Renal Data System 2013 Annual Data Report[J]. Am J Kidney Dis, 2014. 63(1 suppl): A7.
[2] Chirakarnjanakorn S,Navaneethan SD,Francis GS,et al. Cardiovascular impact in patients undergoing maintenance hemodialysis:clinical management considerations [J]. Int J Cardiol,2017,232:12-23.
[3] Bleyer AJ,Hartman J,Brannon PC, et al. Characteristics of sudden death in hemodialysis patients[J]. Kidney Int, 2006,69(12):2268-2273.
[4] Lafrance JP,Nolin L,Senécal L,et al. Predictors and outcome of cardiopulmonary resuscitation (CPR) calls in a large haemodialysis unit over a seven-year period[J]. Nephrol Dial Transplant,2006,21(4):1006-1012.
[5] Santoro A,Mancini E,London G,et al. Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal[J]. Nephrol Dial Transplant,2008,23(4):1415-1421.
[6] Redaelli B,Locatelli F,Limido D,et al. Effect of a new model of hemodialysis potassium removal on the control of ventricular arrhythmias[J]. Kidney Int,1996,50(2): 609-617.
[7] Uhlig K,Berns JS,Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis,Evaluation,and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)[J]. Am J Kidney Dis,2010,55(5):773-799.
[8] Pun PH,Horton JR,Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients[J]. Clin J Am Soc Nephrol,2013,8(5):797-803.
[9] Pun PH,Abdalla S,Block GA,et al. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial[J]. Hemodial Int,2016,20(3):421-431.
[10]Group FT,Chertow GM,Levin NW,et al. In-center hemodialysis six times per week versus three times per week[J]. N Engl J Med,2010,363(24):2287-2300.
[11] Chertow GM,Levin NW,Beck GJ,et al. Long-Term Effects of Frequent In-Center Hemodialysis[J]. J Am Soc Nephrol,2016,27(6):1830-1836.
[12] Foundation NK. KDOQI clinical practice guideline for hemodialysis adequacy:2015 update[J]. Am J Kidney Dis,2015,66(5):884-930.
[13] Tereshchenko LG,Posnack NG. Does plastic chemical exposure contribute to sudden death of patients on dialysis?[J]. Heart Rhythm,2019,16(2):312-317.
[14] Salamon JN,Garcia MJ,Guelfguat M, et al. A heart of stone:rapid metastatic cardiac calcification in an end-stage renal disease patient[J]. J Am Coll Cardiol,2013,61(22):2309.
[15] Okada M,Kyakuno M,Imamura J,et al. An autopsy case of sudden death in renal transplant recipient[J]. Clin Transplant,2002,16 Suppl 8:58-61.
[16] Zhao Y,Chen NX,Shirazi JT,et al. Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease[J]. Heart Rhythm,2016,13(5):1105-1112.
[17] Parfrey PS,Foley RN,Harnett JD ,et al. Outcome and risk factors for left ventricular disorders in chronic uraemia[J]. Nephrol Dial Transplant,1996,11(7):1277-1285.
[18] Franczyk-Skóra B,Gluba A,Banach M,et al. Prevention of sudden cardiac death in patients with chronic kidney disease[J]. BMC Nephrol,2012,13:162.
[19] Shamseddin MK,Parfrey PS. Sudden cardiac death in chronic kidney disease:epidemiology and prevention[J]. Nat Rev Nephrol,2011,7(3):145-154.
[20] Shi JY,Chen C,Xu X,et al. miR-29a promotes pathological cardiac hypertrophy by targeting the PTEN/AKT/mTOR signalling pathway and suppressing autophagy[J]. Acta Physiol,2019, 227 (2):e13323.
[21] Paoletti E,Amidone M,Cassottana P,et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients:a 1-year nonrandomized controlled trial[J]. Am J Kidney Dis,2008,52(2):324-330.
[22] 张耀庭,李烽,朱永翔,等,沙库巴曲/缬沙坦在室性心律失常中的研究进展[J]. 心血管病学进展,2019,40(7): 982-984.
[23] Feng JL. Incidence and predictors of sudden cardiac death after a major non-fatal cardiovascular event[J]. Heart Lung Circ,2019,23.pii:S1443-9506(19)30339-30337.
[24] Schwarz U,Buzello M,Ritz E,et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure[J]. Nephrol Dial Transplant,2000,15(2):218-223.
[25] Kono K,Fujii H,Nakai K,et al. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease[J]. Kidney Int,2012,82(3):344-351.
[26] Ure?a-Torres P,D’Marco L,Raggi P,et al. Valvular heart disease and calcification in CKD: more common than appreciated[J]. Nephrol Dial Transplant,2019,21.pii:gfz133.
[27] Choi MJ,Kim JK,Kim SG,et al. Association between cardiac valvular calcification and myocardial ischemia in asymptomatic high-risk patients with end-stage renal disease[J]. Atherosclerosis,2013,229(2): 369-373.
[28] Cice G,Ferrara L,D’Andrea A,et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy:a prospective, placebo-controlled trial[J]. J Am Coll Cardiol,2003,41(9):1438-1444.
[29] Pun PH,Lehrich RW, Smith SR,et al.Predictors of survival after cardiac arrest in outpatient hemodialysis clinics[J]. Clin J Am Soc Nephrol,2007,2(3):491-500.
相似文献/References:
[1]刘颖,袁美锦.儿童与青少年心脏性猝死的病因和预防[J].心血管病学进展,2019,(6):935.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.024]
LIU Ying,YUAN Meijin.Causes and Prevention of Sudden Cardiac Death in Children and Adolescents[J].Advances in Cardiovascular Diseases,2019,(7):935.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.024]
[2]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(7):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[3]鲁星琴 莫乔莹 陈凤梅 姚亚丽.睡眠呼吸障碍与心力衰竭并发心房颤动的相关性研究现状[J].心血管病学进展,2020,(2):182.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.021]
LU Xingqin,MO Qiaoying,CHENG Fengmei,et al.Research Status of Association Between Sleep-disordered Breathing and Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2020,(7):182.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.021]
[4]孙姣 于晓红 尹晓盟.心室颤动导管消融治疗进展[J].心血管病学进展,2020,(10):1044.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.011]
SUN Jiao,YU Xiaohong,YIN Xiaomeng.Catheter Ablation for Ventricular Fibrillation[J].Advances in Cardiovascular Diseases,2020,(7):1044.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.011]
[5]张海福 张邢炜.血液透析患者冠状动脉介入治疗术后双联抗血小板治疗的进展[J].心血管病学进展,2020,(12):1281.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.014]
ZHANG Haifu,ZHANG Xingwei.Dual Antiplatelet Therapy after Coronary Intervention in Hemodialysis Patients[J].Advances in Cardiovascular Diseases,2020,(7):1281.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.014]
[6]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(7):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
[7]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(7):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[8]杜明亮 王泊然 惠慧 郑晓群.维持血液透析合并冠心病的患者降脂治疗的研究进展[J].心血管病学进展,2023,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.007]
DU Mingliang,WANG Boran,HUI Hui,et al.Lipid-Lowering Therapy in Maintenance Hemodialysis Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2023,(7):1084.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.007]